Aptar Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aptar Pharma

Pharmaceutical Technology Europe

Company name: Aptar Pharma
Address: 36-38 rue de la Princesse, 78430 Louveciennes, France
Telephone: +33 1 39 17 20 20
Fax: +33 1 39 58 12 98
E-mail: guillaume.le_brun@aptar.com
Website: www.aptar.com
No. of employees: 2 280
Date founded: 1947

Aptar Pharma is the segment within the Aptargroup family dedicated to the pharmaceutical market. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world.

Aptar Pharma is market driven with a strong focus on specific therapeutic areas such as as allergic rhinitis, asthma, COPD, pain management, hormone therapies, mucosal vaccines as well as cough & cold ailments.

The Aptar Pharma Prescription Division specializes in novel drug delivery solutions - i.e. pMDIs, DPIs, Spray Pumps and UnitDoses - specific to physician-prescribed medicines while the Consumer Health Care Division offers dispensing solutions adapted to over-the-counter medications.

Our manufacturing facilities are located in Buenos Aires (Argentina), Congers (NY, U.S.A.), Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France) and Suzhou (near Shanghai, R.O.C.).

Approximately 6% of Aptar Pharma’s annual turnover is dedicated to research, development and industrialization of novel products. Our R&D and Marketing staff work closely together in a global market-focused team of 200 people dedicated to satisfying customer needs.

Aptar Pharma R&D centres of excellence are located in Eigeltingen (Germany), Lugano (Switzerland), Le Vaudreuil and Val-de-Reuil (France).

www.aptar.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here